key: cord-0761759-iviw0nt4
authors: Hu, Chao; Shen, Meiying; Han, Xiaojian; Chen, Qian; Li, Luo; Chen, Siyin; Zhang, Jing; Gao, Fengxia; Wang, Wang; Wang, Yingming; Li, Tingting; Li, Shenglong; Huang, Jingjing; Wang, Jianwei; Zhu, Ju; Chen, Dan; Wu, Qingchen; Tao, Kun; Pang, Da; Jin, Aishun
title: Identification of Cross-Reactive CD8+ T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants
date: 2021-06-29
journal: Genes Dis
DOI: 10.1016/j.gendis.2021.05.006
sha: 9ef98d2812dbf4fe7b860bb397f31b51de99a20f
doc_id: 761759
cord_uid: iviw0nt4

Despite the growing knowledge of T cell responses in COVID-19 patients, there is a lack of detailed characterizations for T cell-antigen interactions and T cell functions. Here, with a predicted peptide library from SARS-CoV-2 S and N proteins, restricted to three of the most prominent HLA-A alleles in the Asian population, we found that specific CD8+ T cell responses were identified in over 75% of COVID-19 convalescent patients (15/20). A total of 15 SARS-CoV-2 epitopes from the S and N proteins were identified, and among them, 3 dominant epitopes were further characterized. We found that an epitope from the N protein, N361-369 (KTFPPTEPK), was the most dominant epitope from our selected peptide library. Importantly, we discovered 2 N361-369-specific T cell receptors (TCRs) with high functional avidity that were independent of the CD8 co-receptor. These TCRs exhibited complementary cross-reactivity to several presently reported N361-369 mutant variants, as to the wild-type epitope. Further, the natural functions of these TCRs in the cytotoxic immunity against SARS-CoV-2 were determined with dendritic cells (DCs) and the lung organoid model. We found that the N361-369 epitope could be normally processed and endogenously presented by these different types of antigen presenting cells, to elicit successful activation and effective cytotoxicity of CD8+ T cells ex vivo. Our study evidenced potential mechanisms of cellular immunity to SARS-CoV-2, and illuminated potential ways of viral clearance in COVID-19 patients. These results indicate that utilizing CD8-independent TCRs against SARS-CoV-2-associated antigens may provide functional superiority that is beneficial for the adoptive cell immunotherapies based on natural or genetically engineered T cells. Additionally, this information is highly relevant for the development of the next-generation vaccines with protections against continuously emerged SARS-CoV-2 mutant strains.

(STEMCELL Technologies, Canada). Monocytes were cultured in the DC medium for 141 6 days, which was made with RPMI-1640 medium supplemented with 10% FBS, 100 142 IU/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine (Gibco, USA), 800 143 IU/ml GM-CSF (PeproTech, USA) and 800 IU/ml IL-4 (PeproTech, USA). On day 3, 144 fresh DC media were added to the cultures. On day 6, cells were cryopreserved and 145 stored in liquid nitrogen until used in the assays. (Table S3 ) containing 1 μg/ml collagenase (Sigma-Aldrich, USA) on a 155 shaker at 37°C for 1 hour. The digested lung tissue suspension was sheared using 5 ml 156 plastic Pasteur pipettes before straining over a 100 μm filter. The retained tissue Peptide library 167 To define the SARS-CoV-2-specific CD8 + T cell epitopes of the S and N proteins 168 derived from SARS-CoV-2 reference sequences (GenBank: MN908947). The 169 NetMHCpan 4.0 algorithm 43 was used to analyze the binding of 9-mer peptides 170 derived from the full lengths of SARS-CoV-2 S and N proteins, with HLA-A*02:01, 171 HLA-A*24:02 or HLA-A*11:01. For each allele, binding peptides with high strength 172 (Rank Threshold < 0.5) were selected, and a total of 72 predicted epitopes were 173 generated. Additional 6 SARS-CoV epitopes were selected (Table S4) . 44, 45 Individual 174 peptide's HLA-A specificity was listed in Table S4 . All 78 epitopes were synthesized 175 (GenScript) and dissolved in the corresponding solvents for the subsequent 176 experiments. Detailed information for peptide grouping was summarized in Table S5 . 179 To screen the HLA-A*11:01 phenotypes of the COVID-19 convalescent patients and The supernatants were used for measuring IFN-γ concentrations by ELISA. RFUs -Spontaneous death RFUs).

The ability of T cells to lyse organoids was also measured using LDH-Glo™ 337 Cytotoxicity Assay Kit (Promega, USA) according to the manufacturer's instructions.

The organoids were dissociated to single cells and counted, which was used to infer alleles in the Asian population. We synthesized a peptide library of 72 predicted 383 SARS-CoV-2 epitopes, which overlapped 29 SARS-CoV epitopes, together with 384 additional 6 confirmed SARS-CoV epitopes (see Table S4 in the supplemental 385 material). 44,45 Among these 78 peptides, 62 were from the S protein and 16 were from 386 the N protein, with 3 different HLA-A restrictions (Table S5) .

In parallel, we collected a total of 37 COVID-19 convalescent PBMC samples and Furthermore, the specificities of the P64 reactive TCRs were verified in CD8 +

Jurkat cells, which were transduced with the top 4 dominant TCR clones (TCR 1-4).

Using the P64-HLA-A*11:01 tetramer, we confirmed that only TCR 1 and TCR 4 were P64-specific ( Fig. 2C ; fluorescent signal levels were found between CD8and CD8 + Jurkat cells (Fig. 3B) .

These results were in line with those of the CD4 + and CD8 + T cells (Fig. 3A and B) . approximately 70% target cell lysis was achieved at E:T cell ratio of 40:1 (Fig. 3D ).

The functional activity of TCR 1-and TCR 4-transduced CD4 + T cells was analysed 473 by the production of IFN-γ, IL-2 and TNF-α via cytokine secretion assay. We found 474 that N 361-369 could elicit significant induction of all three cytokines in these CD4 + T 475 cells, comparing to an equimolar amount of DMSO (Fig. 3E) . These results proved that the N 361-369 -specific TCR 1 and TCR 4 could mediate the cytotoxicity of CD8 + T 477 cells and the effector cytokine secretion of CD4 + T cells. other point mutations (Fig. 4B) . Interestingly, we found that N T366I preferably led to 508 an activation of the TCR 1-T cells similar to that of the wild type N 361-369 , and the 509 TCR 4-T cells were mainly activated by N T362I or N F363L (Fig. 4B ). These findings Table S6 ).

Strikingly, we found that 3 out of 4 dominant peptides were derived from the N 574 protein, and accounted for approximately 50% of tested CD8 + T cell reactivity. These These findings strongly suggested that N 361-369 was highly immunogenic and capable 589 to induce robust CD8 + T cell responses to SARS-CoV-2.

Presently, reports for SARS-CoV-2 inducing cellular immune responses were 591 largely focused on the T cell-antigen reactivity. Detailed mechanisms regarding the 592 cellular immunity in COVID-19 convalescent patients were needed for advancing the 593 vaccine development and evaluation. In our study, we found 2 N 361-369 -specific TCRs 594 reported that such independency could only be achieved when the TCR exhibited 598 high-affinity binding to the cognate pMHC. [36] [37] [38] In the affinity test of the 599 N 361-369 -specific TCRs in the transduced CD8 + T or CD4 + T cells, we found that their 600 EC 50 concentrations ranged from 47.17 nM to 380.9 nM (Fig. 4A) . These values are 601 remarkably smaller than most of the reported thresholds of affinity for maximal T-cell 602 activity to peptide epitopes, which were around 5-10 µM. 53-56 Hence, our data 603 evidenced that the N 361-369 -specific TCRs had high affinity and functional avidity, 24 h. Data were presented as mean ± SD, n = 3, **P < 0.01, ***P < 0.001.

Representative data of two independent experiments were shown. 

A pneumonia outbreak associated with a new coronavirus 688 of probable bat origin

An interactive web-based dashboard to track COVID-19 in real 690 time

Tracking Changes in SARS-CoV-2 Spike: 692 Evidence that D614G Increases Infectivity of the COVID-19 Virus

Covid-19: New coronavirus variant is identified in UK

Development of an inactivated vaccine candidate for

A Multibasic Cleavage Site in the Spike Protein 704 of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Structure, Function, and 707 Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by 709

Single-Cell Sequencing of Convalescent Patients' B Cells

A human neutralizing antibody targets the receptor-binding site 712 of SARS-CoV-2

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Human monoclonal antibodies block the binding of SARS-CoV-2 716 spike protein to angiotensin converting enzyme 2 receptor

Targets of T Cell Responses to SARS-CoV-2

Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

SARS-CoV-2-specific T cell immunity in cases of 722

COVID-19 and SARS, and uninfected controls

Phenotype and kinetics of SARS-CoV-2-specific 724

T cells in COVID-19 patients with acute respiratory distress syndrome

Detection of SARS-CoV-2-Specific Humoral and Cellular 727

Immunity in COVID-19 Convalescent Individuals

SARS-CoV-2 Epitopes Are

DNA vaccine protection against SARS-CoV-2 in rhesus 21

Single-shot Ad26 vaccine protects against 22

SARS-CoV-2 mRNA vaccine design enabled by 23

Broad and strong memory CD4(+) and CD8(+) T cells 738 induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

SARS-CoV-2-specific T cell immunity in cases of 741

COVID-19 and SARS, and uninfected controls

Unbiased Screens Show CD8(+) T Cells of

Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike 744

Broad and strong memory CD4(+) and CD8(+) T cells 746 induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Shared Antigen-specific CD8+ T cell Responses Against 749 the SARS-COV-2 Spike Protein in HLAA

SARS-CoV-2-derived peptides define heterologous and 33

Robust T Cell Response Toward Spike, Membrane, 764 and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical 765 COVID-19 Patients

SARS-CoV-2-specific CD8+ T cell responses in 767 convalescent COVID-19 individuals

Influence of human CD8 769 on antigen recognition by T-cell receptor-transduced cells

Human leucocyte antigen class I-redirected anti-tumour 772

CD4(+) T cells require a higher T cell receptor binding affinity for optimal activity than 773 CD8(+) T cells

The Quest for the Best: How TCR Affinity, Avidity, 775 and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses

Novel and shared neoantigen derived from histone 778 3 variant H3.3K27M mutation for glioma T cell therapy

HLA common and well-documented alleles in China

Comprehensive analysis of dengue 782 virus-specific responses supports an HLA-linked protective role for CD8+ T cells

Long-term expanding human 785 airway organoids for disease modeling

A Sequence Homology and SARS-CoV-2

Functional TCR retrieval from single 796 antigen-specific human T cells reveals multiple novel epitopes

A novel, rapid and efficient method 56

Evidence for a TCR affinity threshold delimiting 823 maximal CD8 T cell function

Animal and human RNA 825 viruses: genetic variability and ability to overcome vaccines

Why are RNA virus mutation rates so damn high?

Virus-specific memory CD8 T 829 cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus 830 infection

T cell responses are required for protection from clinical disease 832 and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice

A vaccine targeting the RBD of the S protein of SARS-CoV-2 835 induces protective immunity

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein 837

Nanoparticle Vaccine

Safety, tolerability, and immunogenicity of a recombinant 839 adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, 840 non-randomised, first-in-human trial